Involuntary Groaning Induced by Levodopa Therapy in a Patient With Progressive Supranuclear Palsy
JAMA Neurol 77:1569, Park, J.E., 2020
Withdrawing Amantadine in Dyskinetic Patients with Parkinson Disease
Neurol 82:300-307, Ory-Magne, F.,et al, 2014
Neurostimulation for Parkinsons Disease with Early Motor Complications
NEJM 368:610-622, Rau, W.,et al, 2013
Long-Term Effect of Initiating Pramipexole vs Levodopa in Early Parkinson Disease
Arch Neurol 66:563-570, Parkinson Sutdy Group CALM Cohort Investigators, 2009
Levodopa Addiction in Idiopathic Parkinson Disease
Neurol 65:1508, Borek,L.L &Friedman,J.H., 2005
Levodopa and the Progression of Parkinson's Disease
NEJM 351:2498-2508, The Parkinson Study Group, 2004
Subthalamic DBS Replaces Levodopa in Parkinson's Disease
Neurol 58:396-401, Vingerhoets,F.J.G.,et al, 2002
Dopamine Transporter Brain Imaging to Assess the Effects of Pramipexole vs Levodopa on Parkinson Disease Progression
JAMA 287:1653-1661, Parkinson Study Group, 2002
Safety and Efficacy of Pallidal or Subthalamic Nucleus Stimulation in Advanced PD
Neurol 56:548-551, Volkmann,J.,et al, 2001
Quetiapine for L-Dopa-Induced Psychosis in PD
Neurol 54:1538, Weiner,W.J.,et al, 2000
A Five-Year Study of the Incidence of Dyskinesia in Patients With Early Parkinson's Disease who were Treated with Ropinirole or Levodopa
NEJM 342:1484-1491, Rascol,O.,et al, 2000
Low-Dose Clozapine for the Treatment of Drug-Induced Psychosis in Parkinson's Disease
NEJM 340:757-763,801, The Parkinson Study Group, 1999
An Algorithm (Decision Tree) for the Management of Parkinson's Disease:Trtm Guidelines
Neurol 50:S1-S57, Olanow,C.W.&Koller,W.C., 1998
Managing the Neuropsychiatric Symptoms of Parkinson's Disease
Neurol 50:S33-S38, Lieberman,A., 1998
Investig of PDRG of UK into Excess Mortality Seen/Comb Levodopa & Selegiline Trmt in Pts with Early, Mild Parkinson's Dis
BMJ 316:1191-1196, Ben-Shlomo,Y.,et al, 1998
Tolcapone for Parkinson's Disease
The Medical Letter 40:60-61, , 1998
Catechol-O-Methyltransferase Inhibitors for Treatment of Parkinson's Disease
Lancet 351:1221-1222, Nutt,J.G., 1998
Early Dopaminergic Drug-Induced Hallucinations in Parkinsonian Patients
Neurol 51:811-814, Goetz,C.G.,et al, 1998
Parkinson's Disease
NEJM 339:1044-1053,1130-1143, Lang,A.E.&Lozano,A.M., 1998
Low-Dose Clozapine Improves Dyskinesias in Parkinson's Disease
Neurol 48:658-662, Durif,F.,et al, 1997
Managing the Late Complications of Parkinson's Disease
Neurol 49:549-557, Waters,C.H., 1997
Nonmotor Fluctuations in Patients with Parkinson's Disease
Neurol 47:1180-1183, Hillen,M.E.&Sage,J.I., 1996
Drug Treatment of Parkinson's Disease
BMJ 310:575-579, Quinn,N., 1995
Low-Dose Clozapine in the Treatment of Levodopa-Induced Mental Disturbances in Parkinson's Disease
Neurol 45:432-434, Rabey,J.M.,et al, 1995
Psychosis in Advanced Parkinson's Disease:Treatment with Ondansetron, a 5-HT3 Receptor Antagonist
Neurol 45:1305-1308, Zoldan,J.,et al, 1995
Parkinson's Disease
JNNP 57:672-681, Marsden,C.D., 1994
Levodopa, Melanoma, and Parkinson's Disease
Neurol 43:674-677, Weiner,W.J.,et al, 1993
Olanzapine in the Treatment of Dopaminomimetic Psychosis in Patients with Parkinson's Disease
Neurol 47:1085-1087, Wolters,W.Ch.,et al, 1992
Early Development of Levodopa-Induced Dyskinesias and Response Fluctuations in Young-Onset Parkinson's Disease
Neurol 41:202-205, Kostic,V., 1991
Neuroleptic Malignant Synd in Parkinson's after Withdrawal or Alteration of Dopaminergic Therapy
Arch Int Med 151:794-796, Keyser,D.L.&Rodnitzky,R.L., 1991
Dose-Dependent Memory Impairment in Parkinson's Disease
Neurol 39:438-440, Huber,S.J.,et al, 1989
Continuous Levodopa Infusions to Treat Complex Dystonia in Parkinson's Disease
Neurol 39:888-891, Sage,J.I.,et al, 1989
Dystonia in Parkinson's Disease:Clinical & Pharmacological Features
Ann Neurol 23:73-78, Poewe,W.H.,et al, 1988
Does Levodopa Aggravate Parkinson's Disease
Neurol 38:1410-1416, Blin,J.,et al, 1988
Forms of Dystonia in Patients with Parkinson's Disease
Neurol 37:1009-1011, Kidron,D.&Melamed,E., 1987
Initiation of Levodopa Therapy in Parkinsonisn Patients Should be Delayed Until the Advanced Stages of the Disease
Arch Neurol 43:402-407, Melamen,E., 1986
Dystonia-Parkinson Syndrome:Differential Effects of Levodopa and Dopamine Agonists
Clin Neuropharmacol 9:298-302, Klawans,H.L.&Paleologos,N., 1986
Development of Malignant Melanoma after Levodopa Therapy for Parkinson's Disease, Report of Case & Review
Am J Med 79:119-121, Kochar,A.S., 1985
Levodopa & Melanoma:Three Cases & Review of Literature
JNNP 48:585-588, Rampen,F.H.J., 1985
Sinemet & the Treatment of Parkinsonism
Ann Int Med 94:364-370, Boshes,B., 1981
Complications of Chronic Levodopa Therapy; Long-term Efficacy of Drug Holiday
Neurol 31:473-476, Koller,W.C.,et al, 1981
Parkinsonism With`On-Off'Phenomena-Intravenous Treatment With Levodopa After Major Abdominal Surgery
Arch Neurol 36:32-34, Rosin,A.J.,et al, 1979
Early-Morning Dystonia-A Late Side Effect of Long-Term Levodopa Therapy
Arch Neurol 36:308-310, Melamed,E., 1979
Analysis of the Clinical Problems in Parkinsonism & the Complications of Long-term Levodopa Therapy
Neurol 29:1253-1260, Lesser,R.P.,et al, 1979
Dementia in Parkinson Disease
Ann Neurol 6:355-359, Lieberman,A.,et al, 1979
Respiratory Dyskinesias:Extrapyramidal Dysfunction & Dyspnea
Ann Int Med 88:327, Weiner,W.J.,et al, 1978
Considerations in the Management of Parkinsonism
Neurol 28:5, Fahn,S.,et al, 1978
Drug Therapy of Parkinsonism
NEJM 295:814, Bianchine,J.R., 1976
Drugs that Reduce Efficacy of Levodopa
(Letter) , NEJM 295:153876., Hausner,R., 1976